TY - JOUR
T1 - Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome
T2 - Covizumab-6 observational cohort.
AU - Corominas, H
AU - Castellví, Ivan
AU - Pomar, V
AU - Antonijoan, R
AU - Mur, I
AU - Matas, L
AU - Gich, I
AU - Benito, N de
AU - Laiz, A
AU - Castillo, D
AU - Villamarin, L
AU - Filella, D
AU - Millán, AM
AU - Quijada, María Ángeles
AU - Puig-Campmany, Mireia
AU - Casademont, Jordi
AU - Domingo, P
PY - 2021/2
Y1 - 2021/2
N2 - Although the starting event in COVID-19 is a viral infection some patients present with an over-exuberant inflammatory response, leading to acute lung injury (ALI) and adult respiratory distress syndrome (ARDS). Since IL-6 plays a critical role in the inflammatory response, we assessed the efficacy and safety of tocilizumab (TCZ) in this single-centre, observational study in all Covid-19 in-patient with a proven SARS-CoV-2 rapidly progressing infection to prevent ALI and ARDS. 104 patients with COVID-19 treated with TCZ had a lower mortality rate (5·8%) compared with the regional mortality rate (11%), hospitalized patient's mortality (10%), and slightly lower than hospitalized patients treated with our standard of care alone (6%). We found that TCZ rapidly decreased acute phase reactants, ferritin and liver release of proteins. D-Dimer decreased slowly. We did not observe specific safety concerns. Early administration of IL6-R antagonists in COVID-19 patients with impending hyperinflammatory response, may be safe and effective treatment to prevent, ICU admission and further complications.
AB - Although the starting event in COVID-19 is a viral infection some patients present with an over-exuberant inflammatory response, leading to acute lung injury (ALI) and adult respiratory distress syndrome (ARDS). Since IL-6 plays a critical role in the inflammatory response, we assessed the efficacy and safety of tocilizumab (TCZ) in this single-centre, observational study in all Covid-19 in-patient with a proven SARS-CoV-2 rapidly progressing infection to prevent ALI and ARDS. 104 patients with COVID-19 treated with TCZ had a lower mortality rate (5·8%) compared with the regional mortality rate (11%), hospitalized patient's mortality (10%), and slightly lower than hospitalized patients treated with our standard of care alone (6%). We found that TCZ rapidly decreased acute phase reactants, ferritin and liver release of proteins. D-Dimer decreased slowly. We did not observe specific safety concerns. Early administration of IL6-R antagonists in COVID-19 patients with impending hyperinflammatory response, may be safe and effective treatment to prevent, ICU admission and further complications.
KW - COVID-19
KW - SARS-CoV-2
KW - Tocilizumab
KW - IL-6R antoagonist
KW - Treatment
KW - Cytokine realease syndrome
UR - http://europepmc.org/abstract/med/33189888
U2 - 10.1016/j.clim.2020.108631
DO - 10.1016/j.clim.2020.108631
M3 - Article
C2 - 33189888
VL - 223
JO - Clinical immunology (Orlando, Fla.)
JF - Clinical immunology (Orlando, Fla.)
M1 - 108631
ER -